Advances of synthetic lipoproteins as drug nanovectors

ZHANG Fangrong; WANG Wei

doi:10.11665/j.issn.1000-5048.20160204

Journal of China Pharmaceutical University > 2016 > 47(2): 148-157. > DOI: 10.11665/j.issn.1000-5048.20160204

ZHANG Fangrong, WANG Wei. Advances of synthetic lipoproteins as drug nanovectors[J]. Journal of China Pharmaceutical University, 2016, 47(2): 148-157. DOI: 10.11665/j.issn.1000-5048.20160204

Citation:

ZHANG Fangrong, WANG Wei. Advances of synthetic lipoproteins as drug nanovectors[J]. Journal of China Pharmaceutical University, 2016, 47(2): 148-157. DOI: 10.11665/j.issn.1000-5048.20160204

Citation:

ZHANG Fangrong, WANG Wei. Advances of synthetic lipoproteins as drug nanovectors[J]. Journal of China Pharmaceutical University, 2016, 47(2): 148-157. DOI: 10.11665/j.issn.1000-5048.20160204

PDF (1236 KB)

Advances of synthetic lipoproteins as drug nanovectors

ZHANG Fangrong^1,2,
WANG Wei^1,2

More Information

Graphical Abstract

Abstract

Abstract

Synthetic lipoproteins are efficient nanovectors for targeting delivery of biological drugs, chemical drugs and imaging contrast agents and so on. They have ultra-small particle size, excellent biocompatibility, favorable circulation half-life and specific lipoprotein-receptors-binding capacity of lipoprotein receptors. Compared with traditional natural lipoproteins, synthetic lipoproteins possess both native biochemical properties and functions, and superior drug delivery potentials. This paper introduces the development of lipoproteins as drug nanovectors and reviews preparation methods of synthetic lipoproteins, in vitro and in vivo applications and the approaches employed to expand the limited applications of lipoproteins as drug nanovectors. Further development of synthetic lipoproteins is also proposed.
- synthetic lipoprotein,
- nanovector,
- mimetic peptide,
- drug delivery,
- advances

FullText(HTML)

References (64)

References

[1]	Zhang L,Song J,Cavigiolio G,et al.Morphology and structure of lipoproteins revealed by an optimized negative-staining protocol of electron microscopy[J].J Lipid Res,2011,52(1):175-184.
[2]	Wang RN,Liu CY,Zhou JP,et al.Advanced in the research of lipoprotein-based nanoscale drug delivery systems[J].J China Pharm Univ(中国药科大学学报),2014,45(1):10-16.
[3]	Sabnis N,Lacko AG.Drug delivery via lipoprotein-based carriers:answering the challenges in systemic therapeutics[J].Therapeutic Deliv,2012,3(5):599-608.
[4]	Zhang Z,Chen J,Ding L,et al.HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting[J].Small,2010,6(3):430-437.
[5]	Davis ME, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer[J].Nat Rev Drug Discov 2008,7(9):771-782.
[6]	Dieckmann M, Dietrich MF, Herz J. Lipoprotein receptors—an evolutionarily ancient multifunctional receptor family[J].J Biol Chem,2010,391(11):1341-1363.
[7]	Danilo C, Gutierrez-Pajares JL, Mainieri MA, et al. Scavenger receptor class B type I regulates cellular cholesterol metabolism and cell signaling associated with breast cancer development[J].Breast Cancer Res,2013,15(5):R87.
[8]	Twiddy AL, Cox ME, Wasan KM. Knockdown of scavenger receptor class B type I reduces prostate specific antigen secretion and viability of prostate cancer cells[J].Prostate,2012,72(9):955-965.
[9]	Narasimhan K,Pillay S,Bin Ahmad NR,et al.Identification of a polyoxometalate inhibitor of the DNA binding activity of Sox2[J].ACS Chem Biol,2011,6(6):573-581.
[10]	Guo D,Reinitz F,Youssef M,et al.An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway[J].Cancer Discov,2011,1(5):442-456.
[11]	Leon CG,Locke JA,Adomat HH,et al.Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model[J].Prostate,2010,70(4):390-400.
[12]	Zheng Y,Liu Y,Jin H,et al.Scavenger receptor B1 is a potential biomarker of human nasopharyngeal carcinoma and its growth is inhibited by HDL-mimetic nanoparticles[J].Theranostics,2013,3(7):477.
[13]	Qiu Y,Liu S,Chen H T,et al.Upregulation of caveolin-1 and SR-B1 in mice with non-alcoholic fatty liver disease[J].Hepatobiliary Pancreat Dis Int,2013,12(6):630-636.
[14]	Liu KH,Wang CP,Chang MF,et al.Molecular characterization of photosensitizer-mediated photodynamic therapy by gene expression profiling[J].Hum Exp Toxicol,2014,33(6):629-637.
[15]	Mökelö KM, Traylor M, Oksala N, et al. Association of the novel single-nucleotide polymorphism which increases oxidized low-density lipoprotein levels with cerebrovascular disease events[J].Atherosclerosis,2014,234(1):214-217.
[16]	Lu T,Wen S,Cui Y,et al.Near-infrared fluorescence imaging of murine atherosclerosis using an oxidized low density lipoprotein-targeted fluorochrome[J].Int J Cardiovasc Imaging,2014,30(1):221-231.
[17]	Gordts SC,Singh N,Muthuramu I,et al.Pleiotropic effects of HDL:towards new therapeutic areas for HDL-targeted interventions[J].Curr Mol Med,2014,14(4):481-503.
[18]	Krieger M,Anderson RGW,Goldstein JL,et al.Reconstituted low density lipoprotein:a vehicle for the delivery of hydrophobic fluorescent probes to cells[J].J Supramol Struct,1979,10(4):467-478.
[19]	Vesell ES.Advances in pharmacogenetics and pharmacogenomics[J].J Clin Pharmacol,2000,40(9):930-938.
[20]	Kader A,Pater A.Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells[J].J Controlled Release,2002,80(1):29-44.
[21]	Yang M,Jin H,Chen J,et al.Efficient cytosolic delivery of siRNA using HDL-mimicking nanoparticles[J].Small,2011,7(5):568-573.
[22]	Lin Q,Chen J,Ng KK,et al.Imaging the cytosolic drug delivery mechanism of HDL-like nanoparticles[J].Pharm Res,2014,31(6):1438-1449.
[23]	Jin H,Lovell JF,Chen J,et al.Mechanistic insights into LDL nanoparticle-mediated siRNA delivery[J].Bioconjug Chem,2011,23(1):33-41.
[24]	Walsh MT,Atkinson D.Solubilization of low-density lipoprotein with sodium deoxycholate and recombination of apoprotein B with dimyristoylphosphatidylcholine[J].Biochemistry,1983,22(13):3170-3178.
[25]	Ginsburg GS,Walsh MT,Small DM,et al.Reassembled plasma low density lipoproteins.Phospholipid-cholesterol ester-apoprotein B complexes[J].J Biol Chem,1984,259(10):6667-6673.
[26]	Lundberg B.Preparation of drug-low density lipoprotein complexes for delivery of antitumoral drugs via the low density lipoprotein pathway[J].Cancer Res,1987,47(15):4105-4108.
[27]	Vogel T,Weisgraber KH,Zeevi MI,et al.Human apolipoprotein E expression in Escherichia coli:structural and functional identity of the bacterially produced protein with plasma apolipoprotein E[J].Proc Natl Acad Sci,1985,82(24):8696-8700.
[28]	Esatbeyoglu T, Ulbrich K, Rehberg C, et al. Thermal stability,antioxidant,and anti-inflammatory activity of curcumin and its degradation product 4-vinyl guaiacol[J].Food Funct,2015,6(3):887-893.
[29]	Zhu Q,Zhou Y,Guan M,et al.Low-density lipoprotein-coupled N-succinyl chitosan nanoparticles co-delivering siRNA and doxorubicin for hepatocyte-targeted therapy[J].Biomaterials, 2014,35(22):5965-5976.
[30]	Taratula O,Schumann C,Duong T,et al.Dendrimer-encapsulated naphthalocyanine as a single agent-based theranostic nanoplatform for near-infrared fluorescence imaging and combinatorial anticancer phototherapy[J].Nanoscale,2015,7(9):3888-3902.
[31]	Marotta DE,Cao W,Wileyto EP,et al.Evaluation of bacteriochlorophyll-reconstituted low-density lipoprotein nanoparticles for photodynamic therapy efficacy in vivo[J].Nanomedicine,2011,6(3):475-487.
[32]	Corbin IR,Li H,Chen J,et al.Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents[J].Neoplasia,2006,8(6):488-498.
[33]	Allijn IE,Leong W,Tang J,et al.Gold nanocrystal labeling allows low-density lipoprotein imaging from the subcellular to macroscopic level[J].ACS Nano,2013,7(11):9761-9770.
[34]	Zheng G,Chen J,Li H,et al.Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents[J].Proc Natl Acad Sci U S A,2005,102(49):17757-17762.
[35]	Bricarello DA,Smilowitz JT,Zivkovic AM,et al.Reconstituted lipoprotein:a versatile class of biologically-inspired nanostructures[J].ACS Nano,2010,5(1):42-57.
[36]	Mooberry LK,Nair M,Paranjape S,et al.Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier[J].J Drug Target, 2010,18(1):53-58.
[37]	Shahzad MMK,Mangala LS,Han HD,et al.Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles[J].Neoplasia,2011,13(4):309-319.
[38]	Liu CY, Wang W, Zhou JP, et al.Preparation and evaluation of gambogic acid loaded reconstituted high density lipoprotein nanoparticles[J].J China Pharm Univ(中国药科大学学报),2013,44(4):311-315.
[39]	Sabnis N,Pratap S,Akopova I,et al.Pre-clinical evaluation of rHDL encapsulated retinoids for the treatment of neuroblastoma[J].Front Pediatr,2013,3:1-6.
[40]	Ding Y,Wang W,Feng M,et al.A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy[J].Biomaterials,2012,33(34):8893-8905.
[41]	Sabnis N,Nair M,Israel M,et al.Enhanced solubility and functionality of valrubicin(AD-32)against cancer cells upon encapsulation into biocompatible nanoparticles[J].Int J Nanomedicine,2012,7:975.
[42]	Thaxton CS,Daniel WL,Giljohann DA,et al.Templated spherical high density lipoprotein nanoparticles[J].J Am Chem Soc,2009,131(4):1384-1385.
[43]	McMahon KM,Mutharasan RK,Tripathy S,et al.Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery[J].Nano Lett,2011,11(3):1208-1214.
[44]	Ghosh M,Singh ATK,Xu W,et al.Curcumin nanodisks:formulation and characterization[J].Nanomedicine,2011,7(2):162-167.
[45]	Singh ATK, Ghosh M, Forte TM, et al. Curcumin nanodisk-induced apoptosis in mantle cell lymphoma[J].Leuk Lymphoma,2011,52(8):1537-1543.
[46]	Ghosh M,Ryan R O.ApoE enhances nanodisk-mediated curcumin delivery to glioblastoma multiformecells[J].Nanomedicine,2014,9(6):763-771.
[47]	Ng KK,Lovell JF,Vedadi A,et al.Self-assembled porphyrinnanodiscs with structure-dependent activation for phototherapy and photodiagnostic applications[J].ACS Nano,2013,7(4):3484-3490.
[48]	Ghosh M,Ren G,Simonsen JB,et al.Cationic lipid nanodisks as an siRNA delivery vehicle[J].Biochem Cell Biol,2014,92(3):200-205.
[49]	Duivenvoorden R, Tang J, Cormode DP, et al. A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation[J].Nat Commun,2014,5:1661-1667
[50]	Cho KH.Enhanced delivery of rapamycin by V156K-apoA-I high-density lipoprotein inhibits cellular proatherogenic effects and senescence and promotes tissue regeneration[J].J Gerontol A Biol Sci Med Sci,2011,66(12):1274-1285.
[51]	Bhattacharya P,Grimme S,Ganesh B,et al.Nanodisc-incorporated hemagglutinin provides protective immunity against influenza virus infection[J].J Virol,2010,84(1):361-371.
[52]	Song Q,Huang M,Yao L,et al.Lipoprotein-based nanoparticles rescue the memory loss of mice with Alzheimer′s disease by accelerating the clearance of amyloid-beta[J].ACS Nano,2014,8(3):2345-2359.
[53]	Baillie G,Owens MD,Halbert GW.A synthetic low density lipoprotein particle capable of supporting U937 proliferation in vitro[J].J Lipid Res,2002,43(1):69-73.
[54]	Nikanjam M,Gibbs A R,Hunt C A,et al.Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme[J].J Control Release,2007,124(3):163-171.
[55]	Huntosova V,Buzova D,Petrovajova D,et al.Development of a new LDL-based transport system for hydrophobic/amphiphilic drug delivery to cancer cells[J].Int J Pharm,2012,436(1):463-471.
[56]	Zhang Z,Cao W,Jin H,et al.Biomimetic nanocarrier for direct cytosolic drug delivery[J].Angew Chem Int Ed Engl,2009,48(48):9171-9175.
[57]	Lin Q,Chen J,Ng KK,et al.Imaging the cytosolic drug delivery mechanism of HDL-like nanoparticles[J].Pharm Res,2014,31(6):1438-1449.
[58]	Yang M,Chen J,Cao W,et al.Attenuation of nontargeted cell-kill using a high-density lipoprotein-mimicking peptide-phospholipid nanoscaffold[J].Nanomedicine,2011,6(4):631-641.
[59]	Lin Q, Jin CS, Huang H, et al. Nanoparticle-enabled, image-guided treatment planning of target specific RNAi therapeutics in an orthotopic prostate cancer model[J].Small,2014,10(15):3072-3082.
[60]	Handattu SP,Garber DW,Monroe CE,et al.Oral apolipoprotein AI mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer′s disease[J].Neurobiol Disease,2009,34(3):525-534.
[61]	Yang S,Damiano MG,Zhang H,et al.Biomimetic,synthetic HDL nanostructures for lymphoma[J].Proc Natl Acad Sci,2013,110(7):2511-2516.
[62]	Gomaraschi M,Calabresi L,Rossoni G,et al.Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein AI mimetic peptides[J].J Pharmacol Exp Ther,2008,324(2):776-783.
[63]	Sigalov AB. Nature-inspired nanoformulations for contrast-enhanced in vivo MR imaging of macrophages[J].Contrast Media Mol Imaging,2014,9(5):372-382.
[64]	Khumsupan P,Ramirez R,Khumsupan D,et al.Apolipoprotein E LDL receptor-binding domain-containing high-density lipoprotein:ananovehicle to transport curcumin,an antioxidant and anti-amyloid bioflavonoid[J].Biochim Biophys Acta,2011,1808(1):352-359.

Cited By

Get Citation

PDF

XML

Article views (1271) PDF downloads (3040)

Turn off MathJax

Article Contents

Abstract

References

Advances of synthetic lipoproteins as drug nanovectors

Abstract

References

Catalog

Export File

Citation

Format

Content